TimóteoAT. Heart Failure Trends in Paraíba: Earlier Diagnosis or Better Treatment? – That is One of the Questions. Arq. Bras. Cardiol. 2020;114(2):232-3.
Timóteo,Ana Teresa. Heart Failure Trends in Paraíba: Earlier Diagnosis or Better Treatment? – That is One of the Questions. Arq. Bras. Cardiol., v. 114, n. 2, p. 232-233, Feb. 2020.
Timóteo,A.T. (2020). Heart Failure Trends in Paraíba: Earlier Diagnosis or Better Treatment? – That is One of the Questions. Arq. Bras. Cardiol.,114(2), 232-233.
Timóteo,Ana Teresa. Heart Failure Trends in Paraíba: Earlier Diagnosis or Better Treatment? – That is One of the Questions. Arq. Bras. Cardiol. [online]. 2020, vol. 114, n. 2, [cited 2025-09-07], pp.232-233. Available from: <https://abccardiol.org/en/short-editorial/heart-failure-trends-in-paraiba-earlier-diagnosis-or-better-treatment-that-is-one-of-the-questions/>. ISSN 0066-782X.
Figure 1
Dyslipidemia as a central element in atherosclerotic cardiovascular disease. ASCVD: atherosclerotic cardiovascular disease; LDL-C: low-density lipoprotein cholesterol. Limitations of statin-based therapy (non-exhaustive) include suboptimal LDL-C goal attainment, statin-associated adverse effects that may affect adherence, and potential drug interactions. Residual risk reflects the involvement of multiple underlying pathways.
